Current Status of Liver Transplantation for Hepatitis B Virus

Clinics in Liver Disease

Volumn 15, Issue 4, 2011, Pages 753-764

  Buchanan, Corinne ^a   Tran, Tram T ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral; Genotype; HBcAb positivity; Hepatitis B immune globulin; Hepatitis B virus; Liver transplant

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; PLACEBO; TENOFOVIR;

ANTIVIRAL THERAPY; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; GENOTYPE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; REVIEW; SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; RECURRENCE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80054887663     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.08.011     Document Type: Review

References (79)

1. CDC-Viral hepatitis statistics & surveillance. Available at: Accessed 13, February 2011. http://www.cdc.gov/heptatitis/statistics/index.htm.
2. Kim W.R., Terrault N.A., Pedersen R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137:1680-1686.
3. Jiang L., Jiang L., Cheng N., et al. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009, 15:2489-2499.
4. Gane E.J. The roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008, 2:304-307.
5. Liaw Y., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
6. Samuel D., Roque-Afonso A.M. New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: what will be their impact on the prophylaxis of HBV infection. Liver Transpl 2007, 13:1084-1087.
7. Steinmuller T., Seehofer D., Rayes N., et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35:1528-1535.
8. Lake J.R. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives?. Liver Transpl 2008, 14:S23-S26.
9. van Bommel F., Zollner B., Sarrazin C., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44:318-325.
10. Peters M.G., Anderson J., Lynch P., et al. Randomized control study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44:1110-1116.
11. Janssen H.L., van Zonneveld M., Schalm S.W. Hepatitis B. N Engl J Med 2004, 350(26):2719-2720.
12. Lok A.S., Lai C., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
13. Fontana R.J. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003, 23:89-100.
14. Perrillo R.P., Wright T., Rakela J., et al. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33:424-432.
15. Dienstag J.L., Goldin R.D., Heathcote J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
16. Goodman Z., Dhillon A.P., Wu P.C., et al. Lamivudine treatment reduced progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 1999, 30(Suppl 1):59.
17. Villeneuve J., Condreay L.D., Willems B., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000, 31:207-210.
18. Yao F.Y., Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000, 33:301-307.
19. Kapoor D., Guptan R.C., Wakil S., et al. Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis. J Hepatol 2000, 33:308-312.
20. Yao F.Y., Terrault N.A., Freise C., et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using matched, untreated cohort. Hepatology 2001, 34:411-416.
21. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:1-36.
22. Lo C.M., Liu C.L., Lau G.K., et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005, 11:807-813.
23. Lok A., Tan J. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007, 13:323-326.
24. Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
25. Schiff E., Lai C., Hadziyannis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349-360.
26. Schiff E.R., Neuhaus P., Tillmann H., et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine-resistant HBV in patients post liver transplantation. Hepatology 2001, 34:446A.
27. Lampertico P., Vigano M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445-1451.
28. Perrillo R., Hann H., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126:81-90.
29. Rapti I., Dimou E., Mitsoula P., et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45:307-313.
30. Kamar N., Milioto O., Alric L., et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008, 86:611-614.
31. Gish R.G., Lok A.S., Chang T.T., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437-1444.
32. Tenney D.J., Rose R.E., Baldick C., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
33. Lange C.M., Hofmann W.P., Wunder K., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50(6):2000-2009.
34. Chu C.J., Keefe E.B., Han S.H., et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003, 125:444-451.
35. Lo C.M., Cheung C.K., Lau G.K., et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 2005, 5:1893-1900.
36. Gaglio P., Singh S., Degertekin B., et al. Impact of the hepatitis B genotype on pre- and post-liver transplantation outcomes. Liver Transpl 2008, 14:1420-1427.
37. Devarbhavi H.C., Cohen A.J., Patel R., et al. Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype. Liver Transpl 2002, 8:550-555.
38. Girlanda R., Mohsen A.H., Smith H., et al. Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. Liver Transpl 2004, 10:58-64.
39. McMillan J.S., Bowden D.S., Angus P.W., et al. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996, 24:1371-1378.
40. Gish R.G., McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 2006, 12:S54-S64.
41. Carman W.F., Jacyna M.R., Hadziyannis S., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2:588-591.
42. Akahane Y., Yamanaka T., Suzuki H., et al. Chronic active hepatitis and active hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990, 99:1113-1119.
43. Brunetto M.R., Giarin M., Oliveri F., et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991, 88:4186-4190.
44. Buckwold V.E., Xu Z., Chen M., et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996, 70:5845-5851.
45. Chu A.J., Keefe E.B., Han S.H., et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003, 38(3):619-628.
46. O'Grady J.G., Smith H.M., Davies S.E., et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14:104-111.
47. Buti M., Mas A., Prieto M., et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007, 84:650-654.
48. Baid-Agrawal S., Pascual M., Moradpour D., et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2007, 18:97-115.
49. Durlik M., Gaciong Z., Rowinska D., et al. Long-term results of treatment of hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998, 11:S135-S139.
50. Rostaing L., Modesto A., Baron E., et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996, 74:512-516.
51. Walter T., Dumortier J., Guillaud O., et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007, 7:177-184.
52. Bzowej N., Han S., Degertekin B., et al. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl 2009, 15:1010-1020.
53. Wong S.N., Chu C., Wai C., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analog therapy. Liver Transpl 2007, 13:374-381.
54. Dan Y.Y., Wai C.T., Yeoh K.G., et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost effective analysis. Liver Transpl 2006, 12:736-746.
55. Dumortier J., Chevallier P., Scoazec J.Y., et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long term results. Am J Transplant 2003, 3:999-1002.
56. Han S.H., Ofman J., Holt C., et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000, 6:741-748.
57. Han S.H., Martin P., Edelstein M., et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003, 9:182-187.
58. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28(2):585-589.
59. Saab S., Desai S., Tsaoi D., et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011, 11:511-517.
60. Saab S., Ham M.Y., Stone M.A., et al. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009, 15:413-420.
61. Neff G.W., O'Brien C.B., Nery J., et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004, 10:1372-1378.
62. Naoumov N.V., Ross Lopes A., Burra P., et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001, 34:888-894.
63. Buti M., Mas A., Prieto M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003, 38:811-817.
64. Dodson S.F., De Vera M.E., Bonhalm C.A., et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000, 6:434-439.
65. Barcena R., Del Campo S., Moraleda T., et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 2005, 37:3960-3962.
66. Schiff E.R., Lai C., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419-1427.
67. Marzano A., Lampertico P., Mazzaferro V., et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005, 11:532-538.
68. Angus P.W., Patterson S.J., Strasser S.I., et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplant hepatitis B prophylaxis. Hepatology 2008, 48:1460-1466.
69. United Network for Organ Sharing. Available at: Accessed June 6, 2011. http://www.unos.org.
70. Chotiyaputta W., Pelletier S.J., Fontana R.J., et al. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010, 4:707-715.
71. Burton J.R., Shaw-Stiffel T.A. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practices in the United States. Liver Transpl 2003, 9:837-842.
72. Munoz S.J. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002, 8:S82-S87.
73. Prieto M., Gomez M.D., Berenguer M., et al. De novo hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7:51-58.
74. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009, 15:223-232.
75. Manzarbeitia C., Reich D.J., Ortiz J.A., et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002, 8:556-561.
76. Holt D., Thomas R., Van Thiel D., et al. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002, 137:572-575.
77. Uemoto S., Sugiyama K., Marusawa H., et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998, 65:494-499.
78. Dodson S.F., Issa S., Araya V., et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997, 64:1582-1584.
79. Nery J.R., Nery-Avila C., Reddy K.R., et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (Anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003, 75:1179-1186.